AR126048A1 - Derivados heterocíclicos condensados - Google Patents
Derivados heterocíclicos condensadosInfo
- Publication number
- AR126048A1 AR126048A1 ARP220101450A ARP220101450A AR126048A1 AR 126048 A1 AR126048 A1 AR 126048A1 AR P220101450 A ARP220101450 A AR P220101450A AR P220101450 A ARP220101450 A AR P220101450A AR 126048 A1 AR126048 A1 AR 126048A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- membered heteroaryl
- cycloalkyl
- substituents
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- -1 N( RS)2 Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La solicitud describe compuestos que son derivados heterocíclicos condensados, composiciones farmacéuticas que comprenden estos compuestos, procesos químicos para preparar estos compuestos y su uso en el tratamiento de enfermedades asociadas con una infección por VHB. Reivindicación 1: Un compuesto de fórmula (1), o una forma estereoisomérica o tautomérica de este, en donde: R¹ se selecciona del grupo que consiste en fenilo, heteroarilo de 5 miembros y heteroarilo de 6 miembros, cada uno de los cuales está sustituido por 1, 2 o 3 sustituyentes, estando cada uno de dichos sustituyentes seleccionado independientemente del grupo que consiste en halo, alquilo C₁₋₆, cicloalquilo C₃₋₆, CN, CF₃, CHF₂, OCHF₂ y OCF₃; R² se selecciona del grupo que consiste en H, CHF₂, CF₃, alquilo C₁₋₆, (alquil C₁₋₆)O(alquilo C₁₋₆) y cicloalquilo C₃₋₆; Q representa un anillo seleccionado del grupo que consiste en fenilo, heteroarilo de 5 miembros y heteroarilo de 6 miembros; n representa 0, 1, 2 o 3; cada R³ representa independientemente un sustituyente seleccionado del grupo que consiste en CN, alquilo C₁₋₆, alcoxilo C₁₋₆, cicloalquilo C₃₋₆, heteroarilo de 5 miembros, heteroarilo de 6 miembros, heterociclilo de 4 - 8 miembros, halo, N(RS)₂, S(O)RS y S(O)₂RS, cada uno del alquilo C₁₋₆, alcoxilo C₁₋₆, cicloalquilo C₃₋₆, heteroarilo de 5 miembros, heteroarilo de 6 miembros, heterociclilo de 4 - 8 miembros, N(RS)₂, S(O)RS y S(O)₂RS está sustituido opcionalmente con 1, 2, 3, 4 o 5 sustituyentes, seleccionado cada uno de dichos sustituyentes independientemente del grupo que consiste en halo, hidroxilo, alquilo C₁₋₆ y oxo; RS se selecciona cada uno independientemente del grupo que consiste en H, alquilo C₁₋₆, alcoxilo C₁₋₆ y cicloalquilo C₃₋₆; Rˣ y Rʸ se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₆ y cicloalquilo C₃₋₆; en donde se excluyen los siguientes compuestos: del grupo de fórmulas (2); o una sal o un solvato farmacéuticamente aceptable de este.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021097848 | 2021-06-02 | ||
| CN2022090237 | 2022-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126048A1 true AR126048A1 (es) | 2023-09-06 |
Family
ID=82115850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101450A AR126048A1 (es) | 2021-06-02 | 2022-06-01 | Derivados heterocíclicos condensados |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240279227A1 (es) |
| EP (1) | EP4347036A1 (es) |
| CN (1) | CN117881661A (es) |
| AR (1) | AR126048A1 (es) |
| CA (1) | CA3218641A1 (es) |
| TW (1) | TW202313008A (es) |
| UY (1) | UY39793A (es) |
| WO (1) | WO2022253255A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6935433B2 (ja) * | 2016-06-29 | 2021-09-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | ジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用 |
| CA3138168A1 (en) * | 2019-05-28 | 2020-12-03 | Sandrine Celine Grosse | Fused heterocyclic derivatives |
| WO2022116997A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
-
2022
- 2022-06-01 WO PCT/CN2022/096525 patent/WO2022253255A1/en active Application Filing
- 2022-06-01 EP EP22731468.9A patent/EP4347036A1/en active Pending
- 2022-06-01 UY UY0001039793A patent/UY39793A/es unknown
- 2022-06-01 CN CN202280049863.0A patent/CN117881661A/zh active Pending
- 2022-06-01 US US18/565,664 patent/US20240279227A1/en active Pending
- 2022-06-01 TW TW111120400A patent/TW202313008A/zh unknown
- 2022-06-01 CA CA3218641A patent/CA3218641A1/en active Pending
- 2022-06-01 AR ARP220101450A patent/AR126048A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117881661A (zh) | 2024-04-12 |
| CA3218641A1 (en) | 2022-12-08 |
| TW202313008A (zh) | 2023-04-01 |
| US20240279227A1 (en) | 2024-08-22 |
| EP4347036A1 (en) | 2024-04-10 |
| WO2022253255A1 (en) | 2022-12-08 |
| UY39793A (es) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR126048A1 (es) | Derivados heterocíclicos condensados | |
| AR069494A1 (es) | Derivados de acidos fosfonicos | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR109868A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes con azufre e hidroxilamina | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| AR120773A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| AR116947A1 (es) | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR123241A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR124222A1 (es) | Derivados heterocíclicos condensados | |
| AR096161A1 (es) | Derivados de triazina | |
| PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR130371A1 (es) | Compuestos |